Thymosin alpha-1 is a peptide, a short chain made of protein building blocks.
Researchers first found it in the thymus, a chest gland that helps the body’s defence system develop.
The version made for use as a medicine is called thymalfasin.
Researchers are still studying how it affects cells that help the body fight illness. They have not proved that it helps people by strengthening the body’s defences.
First, put the health concern you hope to address into words. Then ask what care has good evidence for that problem.
Hope and proof
What has the research shown?
An idea about how it might work leaves a question: does it help people with your health problem?
In its 2024 review, the FDA found too little evidence to establish benefit for any of the uses it assessed.
The FDA said these studies of serious illnesses had too few people and problems with how they were planned or carried out. Those problems made it hard to tell whether the treatment helped.
This does not prove thymosin alpha-1 has no effect; the studies did not settle whether it helps.
As of September 28, 2026, researchers were still testing it. The government’s study records include plans for studies, studies still running, and studies that have ended. A place in those records is not proof that the treatment helps.
Ask for the study that fits your concern. Ask what changed for the people in it, and how certain that result is.
The US position
Is there permission to use it?
As of September 28, 2026, there is no FDA-approved thymosin alpha-1 medicine. There is also no official US document approved by the FDA that sets out its uses and warnings.
You may hear about compounding: making a medicine for a particular patient’s needs.
The ingredient rules
As of September 26, 2026, the FDA neither approves compounded medicines nor checks their safety, benefit, and quality before patients receive them.
For a pharmacy preparing a patient’s medicine, this raw ingredient fails all three ingredient rules. It has no entry in the official pharmacy standards books that sets quality requirements for this ingredient. No FDA-approved drug contains it as an ingredient. It is not on the FDA’s list of raw ingredients allowed under these pharmacy rules. These rules do not give the pharmacy permission to make this medicine from the raw ingredient.
What the temporary policy says
The FDA has a temporary policy for some ingredients while it reviews requests to allow them. Under that policy, it plans not to take action against pharmacies using those ingredients if they meet its conditions. Thymosin alpha-1 is outside that group as of September 28, 2026. Even for ingredients in that group, the policy does not give legal permission to make the medicine.
What changed when requests were withdrawn
People or groups sent the FDA requests to let pharmacies use this ingredient, then withdrew those requests. Those requests appear on the FDA’s page, current as of April 22, 2026. It still raises concerns about product quality and the body treating the injected medicine as an invader. The FDA says it lacks enough information to know the full extent of these concerns.
Withdrawing a request does not authorise a pharmacy to make this medicine. It does not change the ingredient rules above.
Why the country matters
In Italy, thymalfasin (Zadaxin) is authorised by prescription as an add-on to flu vaccination for people with weak immune systems, as of September 28, 2026.
That Italian authorisation does not grant permission for US sales.
If someone offers it during a visit, ask for a written answer. Which US rule allows this exact medicine to be made and supplied to me? Ask for the rule’s name and how this product meets it.
Checking a care offer
Carry these with you
What do I ask before agreeing?
It is fine to read from a list. Start with the question that still feels unclear.
Which health problem is this treatment meant to address?
What study supports this for that problem?
What is the exact medicine, and who makes it? Which US rule allows it to be made and supplied to me, and how does it meet that rule?
What other care can we consider, including waiting?
You can discuss your health problem and care needs at an in-person clinic or through a licensed telehealth service. With telehealth, the visit takes place over video, by phone, or through messages online.
Start with the health concern. Ask what training and experience the doctor or other health professional has in caring for that problem.
As of September 26, 2026, your prescriber needs a licence or another form of permission from the state you are in during your visit.
Use the state medical board’s public records to find out if a doctor’s licence is current. Look for any punishment by the board, any limits on the licence, or formal charges still awaiting a decision. What the board publishes varies by state.
If medicine is proposed, ask which pharmacy makes it, then check that pharmacy in the state’s licence records.
Bring the reason for the visit, your medicine and supplement list, and any past test results. Put your main question at the top.
The Federation of State Medical Boards is the national group that state medical boards belong to. Its May 2026 guidance says a patient picking treatment from a menu, without a proper review of their health problem, is not getting proper care.
It also says patients should be able to ask questions once their visit is over.
If understanding the patient’s health problem requires tests or an exam in person, the federation’s visit guidance calls for them.
As of September 26, 2026, the group gives medical boards advice; each state makes its own rules.
Ask what happens next: another visit, a test, a different treatment, or no treatment. Leave with a way to ask more questions.
Question thymosin alpha one offers
What are the concerns?
Ask about problems reported in studies. Also ask how the quality of the medicine you would receive is checked.
The FDA’s 2024 review described soreness, redness, and irritation where a shot went in as the most common reported problems.
Those reports describe medicine made for medical use and given under a health professional’s supervision. They do not show the quality of a bottle offered online.
FDA reviewers raised concerns about unwanted material and clumps in the raw ingredient used for pharmacy-made shots.
Those problems may make the body’s defences treat the injected material as an invader.
In its 2024 summary of the Italian medicine’s instructions, the FDA reports that thymalfasin is ruled out during pregnancy and breastfeeding.
These peptide safety details are dated September 28, 2026.
Bring pregnancy plans, allergies, and medicines that quiet the body’s defences into the conversation. Ask what is still unknown and how that affects the care being proposed.
Which offers give me reason to pause?
A polished page can still leave basic questions unanswered. Look closely at what is being promised.
Calling thymosin alpha-1 “FDA-approved” misstates its US status as of September 28, 2026.
An offer may say “FDA registered”: the business has filed its details with the FDA. It may show a National Drug Code (NDC), a number identifying a product in a government directory. Neither claim means the FDA approved the product, as of September 26, 2026.
Offering prescription medicine with no prescription requirement breaks federal law, as of September 26, 2026.
In its 2026 letters to online sellers, the FDA found that their websites offered products for use as medicines in people. Labels saying “for research use only”—for laboratory study—did not change that finding. These labels do not give permission to sell unapproved medicine for people.
The whole quote
What might I pay?
As of September 28, 2026, there is no approved US product, so there is no US maker’s list price to give.
Ask for a written total for the visit and any proposed care. Choose a time span, such as the first month or the whole treatment plan. Ask for all visit, test, medicine, and other fees within that time. Ask which costs would repeat later.
For insurance, ask the plan about this exact visit, test, and product. A useful question: what would I owe if the claim is denied?